Home LiteratureArticle Details
PMID: 8090783 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse.

Murray AG, Petzelbauer P, Hughes CC, Costa J, Askenase P, Pober JS

Abstract

We developed a chimeric human-severe combined immunodeficient mouse model to study human allograft rejection. Mice received first partial thickness human skin grafts and then, after anastomosis of the mouse with graft human microvessels, human lymphocytes allogeneic to the skin. By 2 weeks, the skin grafts uniformly developed changes that resemble first-set skin rejection in humans. Vascular cell adhesion molecule 1 and major histocompatibility complex class II molecules were induced on the human vascular endothelium at day 6, prior to significant T-cell infiltration. Perivascular human CD4+ and CD8+ T-cell infiltrates were marked by day 11. Some T cells, adjacent to injured human vessels, expressed the cytolytic granule protein perforin. The human microvessels were destroyed by day 16 without significant damage to human keratinocytes or adjacent mouse microvessels. This small animal model may permit evaluation of potential therapeutic reagents that inhibit human T-cell-mediated injury.

MeSH Terms
Animals Graft Rejection Humans Mice Mice, SCID Microcirculation Skin/blood supply Skin Transplantation/immunology,pathology T-Lymphocytes/immunology Transplantation, Heterologous
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Murray A G
Molecular Cardiobiology Program, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06510.
Petzelbauer P
Hughes C C
Costa J
Askenase P
Pober J S
References (19)
19 references, click to expand
  1. Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture.
    J Immunol. 1993 Nov 1;151(9):5062-72 PMID: 7691964
  2. Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution.
    J Infect Dis. 1993 Sep;168(3):630-40 PMID: 8354904
  3. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1.
    J Immunol Methods. 1994 Feb 28;169(1):1-15 PMID: 7907638
  4. Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response.
    J Exp Med. 1979 Aug 1;150(2):322-37 PMID: 379265
  5. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease.
    J Immunol. 1984 Apr;132(4):1804-8 PMID: 6607948
  6. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.
    J Immunol. 1986 Mar 1;136(5):1680-7 PMID: 3485132
  7. Renal target structures in acute allograft rejection: a histochemical study.
    Kidney Int. 1987 Jun;31(6):1311-6 PMID: 3039233
  8. Transfer of a functional human immune system to mice with severe combined immunodeficiency.
    Nature. 1988 Sep 15;335(6187):256-9 PMID: 2970594
  9. Enhanced ELISA: how to measure less than 10 picograms of a specific protein (immunoglobulin) in less than 8 hours.
    FASEB J. 1988 Nov;2(14):3003-9 PMID: 3263291
  10. The scid mutation in mice causes a general defect in DNA repair.
    Nature. 1990 Oct 4;347(6292):479-82 PMID: 2215662
  11. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood.
    J Exp Med. 1992 Feb 1;175(2):503-16 PMID: 1346272
  12. Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral immune response and are a source of immunocytes for the production of human monoclonal antibodies.
    J Immunol. 1992 Feb 15;148(4):1065-71 PMID: 1737926
  13. Chronic human skin graft rejection in severe combined immunodeficient mice engrafted with human PBL from an HLA-presensitized donor.
    Transplantation. 1992 Mar;53(3):659-65 PMID: 1549862
  14. Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions.
    Eur J Immunol. 1992 Jun;22(6):1421-7 PMID: 1534757
  15. Antibody responses to the blood group antigen D in SCID mice reconstituted with human blood mononuclear cells.
    Immunology. 1992 Jun;76(2):229-34 PMID: 1634246
  16. Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules.
    J Clin Invest. 1993 Mar;91(3):986-96 PMID: 7680673
  17. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
    J Immunol. 1993 Apr 15;150(8 Pt 1):3634-42 PMID: 8468492
  18. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection.
    Transplantation. 1993 Jul;56(1):69-75 PMID: 8333070
  19. Engraftment of human synovium into severe combined immune deficient mice. Migration of human peripheral blood T cells to engrafted human synovium and to mouse lymph nodes.
    J Immunol. 1993 Dec 15;151(12):7324-36 PMID: 8258726
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1994-09-13
Pages
9146-50
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC44764
Subset
IM
Grants
NIAMS NIH HHS · P30-AR414942 · United States
NIAID NIH HHS · R37-AI-12211 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]